Item

Points

Innovation criteria

1

 

 

2

 

 

 

3

 

 

 

4

 

 

 

 

 

 

 

5

 

 

 

 

 

 

 

 

 

 

6

 

 

 

 

 

 

 

 

 

7

 

 

 

 

 

 

 

 

 

 

8

 

 

 

 

 

 

 

 

75

 

 

75

 

 

 

50

 

 

 

50

 

 

 

 

 

 

 

50

 

 

 

 

 

 

 

 

 

 

50

 

 

 

 

 

 

 

 

 

25

 

 

 

 

 

 

 

 

 

 

25

 

 

 

 

 

 

 

 

 

At least 50% of the company’s total expenses for the previous income year is expenditure that the company can notionally deduct for that income year under section 355-205 (about R&D expenditure). 

 

The company has received an Accelerating Commercialisation Grant under the program administered by the Commonwealth known as the Entrepreneurs’ Programme.​

 

At least 15%, but less than 50%, of the company’s total expenses for the previous income year is expenditure that the company can notionally deduct for that income year under section 355-205 (about R&D expenditure).

 

(a) the company has completed or is undertaking an accelerator program that:

 

    (i) provides time-limited support for entrepreneurs with start-up businesses; and

 

    (ii) is provided to entrepreneurs that are selected in an open, independent, and competitive manner; and

 

(b) the entity providing that program has been providing that, or other accelerator programs for entrepreneurs, for at least 6 months; and

 

(c) such programs have been completed by at least one cohort of entrepreneurs.

 

1. ​a total of at least $50,000 has been paid for *equity interest that are *share in the company; and

 

2. the company issued those shares to one or more entities that:

 

1. were not *associates of the company immediately before the issue of those shares; and

 

2. (ii) did not *acquire those shares primarily to assist another entity become entitled to a *tax offset (or a modified CGT treatment) under this Subdivision; and

 

(c) the company issued those shares at least one day before the test time.

 

(a) the company has rights (including equitable rights) under a *Commonwealth law as:

 

   (i) the patentee, or a licensee, of a standard patent; or

 

   (ii) the owner, or a licensee, of a plant breeder’s right;

 

granted in Australia within the last 5 years (ending at the test time); or

 

(b) the company has equivalent rights under a *foreign law.

Unless item 6 applies to the company at the test time:

(a) the company has rights (including equitable rights) under a *Commonwealth law as:

  

1. the patentee, or a licensee, of an innovation patent granted and certified in Australia; or

  

2. the owner, or a licensee, of a registered design registered in Australia;

 

within the last 5 years (ending at the test time); or

 

b) the company has equivalent rights under a *foreign law.

​The company has a written agreement with:

 

1. an institution or body listed in Schedule 1 to the Higher Education Funding Act 1988 (about institutions or bodies eligible for special research assistance); or

 

2. an entity registered under section 29A of the Industry Research and Development Act 1986 (about research service providers);

 

to co-develop and commercialise a new, or significantly improved, product, process, service or marketing or organisational method.